In vivo experiments on a MET-resistant gastric cancer cell line revealed that EGFR signaling became the primary and independent driver for the downstream signaling pathway mitogen-activated protein kinase (MAPK)/extracellular signal-related kinase (ERK) (21). The gene discussed is EGFR; the disease is gastric cancer.